PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
March 7, 2026Cancer Research

Abstract IA003: Boosting the immune system to counter resistance to KRAS inhibitory drugs in lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

JDJulian Downward

Discussion

Loading...

Member takes

Overview

Preclinical model demonstrates enhanced immune responses eliminate KRAS-inhibitor-resistant cells, suggesting new therapeutic strategies.

Key Points

  • To explore strategies for preventing resistance to KRAS-G12C inhibitory drugs by enhancing immune responses.
  • Developed preclinical model mimicking KRAS drug resistance.
  • Co-engrafted isogenic KRAS-G12C and G12D cells.
  • Applied KRAS-G12C inhibitors with immune-enhancing therapies.
  • Examined immune microenvironment alterations post-treatment.
  • Conducted transcriptional profiling of drug-resistant cells.
  • Monotherapy with KRAS inhibitors led to rapid outgrowth of resistant cells.
  • Combination therapies eliminated drug-resistant cells through immune-mediated bystander killing.
  • Increased inflammatory macrophages and influx of NK and CD8+ T cells observed.
  • Enhanced interferon response noted in resistant cells following treatment.
  • Resistance linked to the ability to respond to interferon signaling.

Cite This Study

Julian Downward (2026) studied this question.

synapsesocial.com/papers/69abc2175af8044f7a4eb48fhttps://doi.org/10.1158/1538-7445.rasoncother26-ia003
View Full Paper
Ask AI
Bookmark
Share